Rajnish Mehrotra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8537511/publications.pdf

Version: 2024-02-01

235 papers	14,158 citations	17440 63 h-index	24258 110 g-index
239 all docs	239 docs citations	239 times ranked	10843 citing authors

#	Article	IF	Citations
1	KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. American Journal of Kidney Diseases, 2015, 66, 884-930.	1.9	822
2	Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1089-1096.	4.5	470
3	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International, 2020, 97, 1117-1129.	5.2	407
4	Similar Outcomes With Hemodialysis and Peritoneal Dialysis in Patients With End-Stage Renal Disease. Archives of Internal Medicine, 2011, 171, 110-8.	3.8	398
5	Understanding Sources of Dietary Phosphorus in the Treatment of Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 519-530.	4.5	395
6	Changes in the worldwide epidemiology of peritoneal dialysis. Nature Reviews Nephrology, 2017, 13, 90-103.	9.6	384
7	The Current State of Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2016, 27, 3238-3252.	6.1	366
8	Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. American Journal of Clinical Nutrition, 2008, 88, 1511-1518.	4.7	291
9	Serum and Dialysate Potassium Concentrations and Survival in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 999-1007.	4.5	288
10	Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. Kidney International, 2005, 68, 378-390.	5.2	269
11	The Obesity Paradox and Mortality Associated With Surrogates of Body Size and Muscle Mass in Patients Receiving Hemodialysis. Mayo Clinic Proceedings, 2010, 85, 991-1001.	3.0	268
12	Vitamin D Supplementation in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 50-62.	4.5	264
13	The current and future landscape of dialysis. Nature Reviews Nephrology, 2020, 16, 573-585.	9.6	252
14	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	5.2	235
15	Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2008, 19, 2193-2203.	6.1	217
16	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 2022, 42, 110-153.	2.3	209
17	Serum Albumin as a Predictor of Mortality in Peritoneal Dialysis: Comparisons With Hemodialysis. American Journal of Kidney Diseases, 2011, 58, 418-428.	1.9	199
18	Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study. American Journal of Kidney Diseases, 2016, 68, 256-265.	1.9	186

#	Article	IF	Citations
19	Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney International, 2009, 76, 977-983.	5.2	184
20	POOR NUTRITIONAL STATUS AND INFLAMMATION: Metabolic Acidosis and Malnutritionâ€Inflammation Complex Syndrome in Chronic Renal Failure. Seminars in Dialysis, 2004, 17, 455-465.	1.3	160
21	Vitamin D and the Cardiovascular System. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1515-1522.	4.5	159
22	Maintenance Dialysis throughout the World in Years 1990 and 2010. Journal of the American Society of Nephrology: JASN, 2015, 26, 2621-2633.	6.1	159
23	Diets and enteral supplements for improving outcomes in chronic kidney disease. Nature Reviews Nephrology, 2011, 7, 369-384.	9.6	147
24	Hypovitaminosis D in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1144-1151.	4.5	141
25	NUTRITIONALMANAGEMENT OFMAINTENANCEDIALYSISPATIENTS: Why Aren't We Doing Better?. Annual Review of Nutrition, 2001, 21, 343-379.	10.1	140
26	Chronic Peritoneal Dialysis in the United States. Journal of the American Society of Nephrology: JASN, 2007, 18, 2781-2788.	6.1	136
27	Comparing Mortality of Peritoneal and Hemodialysis Patients in the First 2 Years of Dialysis Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 619-628.	4.5	133
28	Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney International, 2005, 67, 1070-1077.	5.2	132
29	Racial Differences in Mortality Among Those with CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1403-1410.	6.1	127
30	Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2016, 27, 3758-3768.	6.1	126
31	Glycemic Control and Survival in Peritoneal Dialysis Patients with Diabetes Mellitus. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1041-1048.	4.5	123
32	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I â€“ Assessment and Management of Various Cardiovascular Risk Factors. Peritoneal Dialysis International, 2015, 35, 379-387.	2.3	123
33	Reimbursement of Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1291-1298.	6.1	121
34	A Palliative Approach to Dialysis Care. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2203-2209.	4.5	120
35	An analysis of dialysis training in the United States and Canada. American Journal of Kidney Diseases, 2002, 40, 152-160.	1.9	118
36	Serum Potassium and Cause-Specific Mortality in a Large Peritoneal Dialysis Cohort. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1272-1284.	4.5	118

#	Article	IF	Citations
37	Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney International, 2003, 64, 263-271.	5.2	109
38	Association of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex. American Journal of Kidney Diseases, 2010, 55, 100-112.	1.9	106
39	The outcomes of continuous ambulatory and automated peritoneal dialysis are similar. Kidney International, 2009, 76, 97-107.	5.2	104
40	Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 74-83.	4.5	101
41	Symptom Prioritization among Adults Receiving In-Center Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 735-745.	4.5	100
42	Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney International, 2004, 66, 2022-2031.	5.2	93
43	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Diseases, 2020, 75, 404-412.	1.9	92
44	Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. Journal of Bone and Mineral Research, 2010, 25, 2724-2734.	2.8	82
45	Organic and inorganic dietary phosphorus and its management in chronic kidney disease. Iranian Journal of Kidney Diseases, 2010, 4, 89-100.	0.1	82
46	Effect of Age and Dialysis Vintage on Obesity Paradox in Long-term Hemodialysis Patients. American Journal of Kidney Diseases, 2014, 63, 612-622.	1.9	81
47	Association of Cumulatively Low or High Serum Calcium Levels with Mortality in Long-Term Hemodialysis Patients. American Journal of Nephrology, 2010, 32, 403-413.	3.1	80
48	Improvement of nutritional status after initiation of maintenance hemodialysis. American Journal of Kidney Diseases, 2002, 40, 133-142.	1.9	79
49	Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney International, 2010, 77, 1107-1114.	5.2	78
50	Dialysis Modality and Correction of Uremic Metabolic Acidosis: Relationship with All-Cause and Cause-Specific Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 254-264.	4.5	78
51	Association of Medicaid Expansion With 1-Year Mortality Among Patients With End-Stage Renal Disease. JAMA - Journal of the American Medical Association, 2018, 320, 2242.	7.4	78
52	Diabetes and progression of coronary calcium under the influence of statin therapy. American Heart Journal, 2005, 149, 695-700.	2.7	77
53	Racial and Ethnic Disparities in Use of and Outcomes with Home Dialysis in the United States. Journal of the American Society of Nephrology: JASN, 2016, 27, 2123-2134.	6.1	77
54	Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2146-2155.	0.7	75

#	Article	IF	Citations
55	An international Delphi survey helped develop consensus-based core outcome domains for trialsÂin peritoneal dialysis. Kidney International, 2019, 96, 699-710.	5.2	73
56	Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis. Annals of Internal Medicine, 2019, 170, 369.	3.9	73
57	Racial and Ethnic Differences in the Association of Body Mass Index and Survival in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 58, 574-582.	1.9	72
58	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney International, 2019, 95, 973-982.	5.2	70
59	Comparative Outcomes Between Continuous Ambulatory and Automated Peritoneal Dialysis: A Narrative Review. American Journal of Kidney Diseases, 2014, 63, 1027-1037.	1.9	68
60	Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1317-1328.	4.5	67
61	Novel Equations to Estimate Lean Body Mass in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 57, 130-139.	1.9	67
62	Considerations in the optimal preparation of patients for dialysis. Nature Reviews Nephrology, 2012, 8, 381-389.	9.6	67
63	Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1988-1999.	4.5	67
64	Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney International, 2005, 68, 1258-1266.	5.2	63
65	Hypomagnesemia and Mortality in Incident HemodialysisÂPatients. American Journal of Kidney Diseases, 2015, 66, 1047-1055.	1.9	63
66	Estimated GFR and Circulating 24,25-Dihydroxyvitamin D3ÂConcentration: A Participant-Level Analysis of 5 Cohort Studies and Clinical Trials. American Journal of Kidney Diseases, 2014, 64, 187-197.	1.9	62
67	How to Overcome Barriers and Establish a Successful Home HD Program. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 2023-2032.	4.5	61
68	Fostering Innovation in Symptom Management among Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 150-160.	4.5	60
69	Peritoneal Equilibration Test and Patient Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1990-2001.	4.5	59
70	Association of Thyroid Functional Disease With Mortality in a National Cohort of Incident Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1386-1395.	3.6	57
71	Patient and Other Stakeholder Engagement in Patient-Centered Outcomes Research Institute Funded Studies of Patients with Kidney Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1703-1712.	4.5	56
72	Ownership Patterns of Dialysis Units and Peritoneal Dialysis in the United States: Utilization and Outcomes. American Journal of Kidney Diseases, 2009, 54, 289-298.	1.9	55

#	Article	IF	Citations
73	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II â€“ Management of Various Cardiovascular Complications. Peritoneal Dialysis International, 2015, 35, 388-396.	2.3	55
74	No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney International, 2013, 84, 989-997.	5.2	54
75	The changing landscape of home dialysis in the United States. Current Opinion in Nephrology and Hypertension, 2014, 23, 586-591.	2.0	53
76	Treatment frequency and mortality among incident hemodialysis patients in the United States comparing incremental with standard and more frequent dialysis. Kidney International, 2016, 90, 1071-1079.	5.2	53
77	Dialysis Modality and Outcomes in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 332-341.	4.5	52
78	Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrology Dialysis Transplantation, 2016, 31, 1310-1319.	0.7	51
79	Standardized Outcomes in Nephrologyâ€”Peritoneal Dialysis (SONG-PD): Study Protocol for Establishing a Core Outcome Set in PD. Peritoneal Dialysis International, 2017, 37, 639-647.	2.3	50
80	An Update on the Comparisons of Mortality Outcomes of Hemodialysis and Peritoneal Dialysis Patients. Seminars in Nephrology, 2011, 31, 152-158.	1.6	49
81	Neighborhood Location, Rurality, Geography, and Outcomes of Peritoneal Dialysis Patients in the United States. Peritoneal Dialysis International, 2012, 32, 322-331.	2.3	49
82	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcification and Disordered Mineral Metabolism in Dialysis Patients. Seminars in Dialysis, 2007, 20, 139-143.	1.3	48
83	Predictors of treatment with dialysis modalities in observational studies for comparative effectiveness research. Nephrology Dialysis Transplantation, 2015, 30, 1208-1217.	0.7	48
84	Pharmacokinetic Assessment in Patients Receiving Continuous RRT. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 159-164.	4.5	48
85	Sex Differences in Hospitalizations with Maintenance Hemodialysis. Journal of the American Society of Nephrology: JASN, 2017, 28, 2721-2728.	6.1	47
86	Impact of Obesity on Modality Longevity, Residual Kidney Function, Peritonitis, and Survival Among Incident Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2018, 71, 802-813.	1.9	46
87	Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. Nephrology Dialysis Transplantation, 2020, 35, 1949-1958.	0.7	46
88	Comparative Mortalityâ€“Predictability Using Alkaline Phosphatase and Parathyroid Hormone in Patients on Peritoneal Dialysis and Hemodialysis. Peritoneal Dialysis International, 2014, 34, 732-748.	2.3	45
89	Association of Body Mass Index with Mortality in Peritoneal Dialysis Patients: A Systematic Review and Meta-Analysis. Peritoneal Dialysis International, 2016, 36, 315-325.	2.3	43
90	Advancing American Kidney Health. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1788-1788.	4.5	42

#	Article	IF	Citations
91	ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention. Peritoneal Dialysis International, 2021, 41, 352-372.	2.3	42
92	Pre-dialysis serum sodium and mortality in a national incident hemodialysis cohort. Nephrology Dialysis Transplantation, 2016, 31, 992-1001.	0.7	41
93	Treatment of advanced renal failure: Low-protein diets or timely initiation of dialysis?. Kidney International, 2000, 58, 1381-1388.	5.2	40
94	Assessment of Glycemic Control in Dialysis Patients with Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1520-1522.	4.5	40
95	Indication for Dialysis Initiation and Mortality in Patients With Chronic Kidney Failure: A Retrospective Cohort Study. American Journal of Kidney Diseases, 2017, 69, 41-50.	1.9	40
96	Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians: A Multicenter Study. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1437-1445.	4.5	39
97	Predictive Score for Posttransplantation Outcomes. Transplantation, 2017, 101, 1353-1364.	1.0	39
98	Battleground. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 168-173.	4.5	38
99	Disordered Mineral Metabolism and Vascular Calcification in Nondialyzed Chronic Kidney Disease Patients. , 2006, 16, 100-118.		37
100	Serum Magnesium Levels and Hospitalization and Mortality in Incident Peritoneal Dialysis Patients: A Cohort Study. American Journal of Kidney Diseases, 2016, 68, 619-627.	1.9	37
101	Protein and energy nutrition among adult patients treated with chronic peritoneal dialysis. Advances in Chronic Kidney Disease, 2003, 10, 194-212.	2.1	36
102	Mortality Associated with Dose Response of Erythropoiesis-Stimulating Agents in Hemodialysis versus Peritoneal Dialysis Patients. American Journal of Nephrology, 2012, 35, 198-208.	3.1	36
103	Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4054-4061.	3.6	36
104	Correction of Metabolic Acidosis to Ameliorate Wasting in Chronic Kidney Disease: Goals and Strategies. Seminars in Nephrology, 2009, 29, 67-74.	1.6	35
105	Timing of Dialysis Initiation: What Has Changed Since IDEAL?. Seminars in Nephrology, 2017, 37, 181-193.	1.6	35
106	Peritoneal dialysis: an underutilized modality. Current Opinion in Nephrology and Hypertension, 2010, 19, 573-577.	2.0	34
107	Relationship of body size and initial dialysis modality on subsequent transplantation, mortality and weight gain of ESRD patients. Nephrology Dialysis Transplantation, 2012, 27, 3631-3638.	0.7	33
108	The intact nephron hypothesis in reverse: an argument to support incremental dialysis. Nephrology Dialysis Transplantation, 2015, 30, 1602-1604.	0.7	32

#	Article	IF	Citations
109	Extended-hours hemodialysis is associated withÂlower mortality risk in patients with end-stageÂrenal disease. Kidney International, 2016, 90, 1312-1320.	5.2	32
110	Comparing Mandated Health Care Reforms. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1535-1543.	4.5	31
111	Insights into nephrologist training, clinical practice, and dialysis choice. Hemodialysis International, 2012, 16, 242-251.	0.9	31
112	Association of Vascular Access Type with Mortality, Hospitalization, and Transfer to In-Center Hemodialysis in Patients Undergoing Home Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 298-307.	4.5	31
113	Dietary protein requirements and dialysate protein losses in chronic peritoneal dialysis patients. Peritoneal Dialysis International, 2007, 27, 192-5.	2.3	31
114	Association of Hemoglobin and Survival in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1973-1981.	4.5	30
115	Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient. Hemodialysis International, 2008, 12, 16-22.	0.9	29
116	Associations Between Access to Care and Awareness of CKD. American Journal of Kidney Diseases, 2012, 59, S16-S23.	1.9	29
117	Vitamin D and Cardiovascular Disease: Potential Role in Health Disparities. Journal of Health Care for the Poor and Underserved, 2011, 22, 23-38.	0.8	28
118	Insulin resistance in chronic kidney disease: a step closer to effective evaluation and treatment. Kidney International, 2014, 86, 243-245.	5.2	26
119	Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2440-2449.	3.6	26
120	The Evolving Ethics of Dialysis in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 704-709.	4.5	26
121	Effect of high-normal compared with low-normal arterial pH on protein balances in automated peritoneal dialysis patients. American Journal of Clinical Nutrition, 2009, 90, 1532-1540.	4.7	25
122	Prevalence and Prognostic Significance of Renal Artery Calcification in Patients with Diabetes and Proteinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2093-2100.	4.5	24
123	Initiation of Dialysis Should be Timely: Neither Early Nor Late. Seminars in Dialysis, 2013, 26, 644-649.	1.3	24
124	A Pilot Randomized Crossover Trial Assessing the Safety and Short-Term Effects of Pomegranate Supplementation in Hemodialysis Patients. , 2015, 25, 40-49.		24
125	Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial. Nephrology Dialysis Transplantation, 2017, 32, gfw323.	0.7	24
126	Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. Journal of Diabetes and Its Complications, 2016, 30, 1467-1472.	2.3	23

#	Article	IF	Citations
127	Adverse effects of systemic glucose absorption with peritoneal dialysis. Current Opinion in Nephrology and Hypertension, 2013, 22, 663-668.	2.0	22
128	Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 1024-1031.	2.3	22
129	Peritoneal Dialysis Access Associated Infections. Advances in Chronic Kidney Disease, 2019, 26, 23-29.	1.4	22
130	KDOQI US Commentary on the 2020 ISPD Practice Recommendations for Prescribing High-Quality Goal-Directed Peritoneal Dialysis. American Journal of Kidney Diseases, 2021, 77, 157-171.	1.9	22
131	Patient and Technique Survival of Older Adults with Esrd Treated with Peritoneal Dialysis. Peritoneal Dialysis International, 2015, 35, 612-617.	2.3	21
132	Urine Complement Proteins and the Risk of Kidney Disease Progression and Mortality in Type 2 Diabetes. Diabetes Care, 2018, 41, 2361-2369.	8.6	21
133	ASN End-Stage Renal Disease Task Force. Journal of the American Society of Nephrology: JASN, 2010, 21, 1235-1237.	6.1	20
134	Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients. American Journal of Nephrology, 2013, 37, 413-420.	3.1	20
135	Serum sodium and mortality in a national peritoneal dialysis cohort. Nephrology Dialysis Transplantation, 2016, 32, gfw254.	0.7	20
136	Predictors of early mortality and readmissions among dialysis patients undergoing lower extremity amputation. Journal of Vascular Surgery, 2018, 68, 1505-1516.	1.1	20
137	Development and Content Validity of a Patient-Reported Experience Measure for Home Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 588-598.	4.5	20
138	Racial Differences in Mortality and ESRD. American Journal of Kidney Diseases, 2008, 52, 205-208.	1.9	19
139	Association of Pretransplant Serum Phosphorus with Posttransplant Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2712-2721.	4.5	19
140	Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing. Nephrology Dialysis Transplantation, 2014, 29, 2235-2243.	0.7	19
141	Implications of a Nephrology Workforce Shortage for Dialysis Patient Care. Seminars in Dialysis, 2011, 24, 275-277.	1.3	18
142	The Kidney Research National Dialogue. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1806-1811.	4.5	18
143	Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents. Health Services Research, 2015, 50, 790-808.	2.0	18
144	Survival of Elderly Adults Undergoing Incident Home Hemodialysis and Kidney Transplantation. Journal of the American Geriatrics Society, 2016, 64, 2003-2010.	2.6	18

#	Article	IF	Citations
145	Concurrence of Serum Creatinine and Albumin With Lower Risk for Death in Twice-Weekly Hemodialysis Patients. , 2017, 27, 26-36.		18
146	Hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria: A new syndrome?. American Journal of Kidney Diseases, 1997, 29, 106-114.	1.9	17
147	Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. Nature Clinical Practice Nephrology, 2008, 4, 639-642.	2.0	17
148	An Estimation of the Prevalence and Progression of Chronic Kidney Disease in a Rural Diabetic Cambodian Population. PLoS ONE, 2014, 9, e86123.	2.5	16
149	Mean platelet volume and mortality risk in a national incident hemodialysis cohort. International Journal of Cardiology, 2016, 220, 862-870.	1.7	16
150	Weekly Standard Kt/Vurea and Clinical Outcomes in Home and In-Center Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 445-455.	4.5	16
151	Lessons from Haiti on Disaster Relief. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2122-2129.	4.5	15
152	Peritoneal Dialysisâ€“Associated Peritonitis with Simultaneous Exit-Site Infection. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 126-130.	4.5	15
153	Counterpoint: Twice-Weekly Hemodialysis Should Be an Approach of Last Resort Even in Times of Dialysis Unit Stress. Journal of the American Society of Nephrology: JASN, 2020, 31, 1143-1144.	6.1	15
154	Calculating estimated glomerular filtration rate without the race correction factor: Observations at a large academic medical system. Clinica Chimica Acta, 2021, 520, 16-22.	1.1	15
155	The challenge of insomnia for patients on haemodialysis. Nature Reviews Nephrology, 2021, 17, 147-148.	9.6	15
156	Low Protein Diets Are Not Needed in Chronic Renal Failure. Mineral and Electrolyte Metabolism, 1999, 25, 311-316.	1.1	14
157	Cardiovascular Implications of Chronic Kidney Disease in Older Adults. Drugs and Aging, 2008, 25, 241-253.	2.7	14
158	Evaluation of Racial, Ethnic, and Socioeconomic Disparities in Initiation of Kidney Failure Treatment During the First 4 Months of the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2127369.	5.9	14
159	Choice of dialysis modality. Kidney International, 2011, 80, 909-911.	5.2	13
160	Nutritional Issues in Peritoneal Dialysis Patients: How Do They Differ From That of Patients Undergoing Hemodialysis?. , 2013, 23, 237-240.		13
161	Is Early Initiation of Dialysis Harmful?. Seminars in Dialysis, 2014, 27, 250-252.	1.3	13
162	Peritoneal dialysis education: Challenges and innovation. Seminars in Dialysis, 2018, 31, 107-110.	1.3	13

#	Article	IF	Citations
163	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. Kidney International, 2021, 100, 1101-1111.	5.2	13
164	Peritoneal dialysis penetration in the United States: march toward the fringes?. Peritoneal Dialysis International, 2006, 26, 419-22.	2.3	13
165	Age-related decline in serum parathyroid hormone in maintenance hemodialysis patients is independent of inflammation and dietary nutrient intake. , 2004, 14, 134-142.		12
166	Dialysis Therapies. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 812-814.	4.5	12
167	Changes in symptom burden and physical performance with initiation of dialysis in patients with chronic kidney disease. Hemodialysis International, 2015, 19, 147-150.	0.9	12
168	Bridging the Care Gap Around Dialysis Initiation: Is CKD Education Part of the Solution?. American Journal of Kidney Diseases, 2011, 58, 160-161.	1.9	11
169	Development and Validation of a Novel Laboratory-Specific Correction Equation for Total Serum Calcium and Its Association With Mortality Among Hemodialysis Patients. Journal of Bone and Mineral Research, 2017, 32, 549-559.	2.8	11
170	Education, research, peritoneal dialysis, and the North American chapter of the International Society for Peritoneal Dialysis. Peritoneal Dialysis International, 2005, 25, 14-5.	2.3	11
171	Is Dorothy Correct? The Role of Patient Education in Promoting Home Dialysis. Seminars in Dialysis, 2013, 26, 138-142.	1.3	10
172	Alkaline phosphatase: Better than <scp>PTH</scp> as a marker of cardiovascular and bone disease?. Hemodialysis International, 2014, 18, 720-724.	0.9	10
173	Components of A Successful Peritoneal Dialysis Program. Seminars in Nephrology, 2017, 37, 10-16.	1.6	10
174	Sleep-HD trial: short and long-term effectiveness of existing insomnia therapies for patients undergoing hemodialysis. BMC Nephrology, 2020, 21, 443.	1.8	10
175	Coronary artery calcification in nondialyzed patients with chronic kidney diseases. American Journal of Kidney Diseases, 2005, 45, 963.	1.9	9
176	What Should Define Optimal Correction of Metabolic Acidosis in Chronic Kidney Disease?. Seminars in Dialysis, 2010, 23, 411-414.	1.3	9
177	Could longer and more frequent haemodialysis improve outcomes?. Nature Reviews Nephrology, 2013, 9, 74-75.	9.6	9
178	Diagnostic Testing for Peritonitis in Patients Undergoing Peritoneal Dialysis. Seminars in Dialysis, 2014, 27, 602-606.	1.3	9
179	Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients. BMC Nephrology, 2015, 16, 79.	1.8	9
180	Initial Session Duration and Mortality Among IncidentÂHemodialysis Patients. American Journal of Kidney Diseases, 2017, 70, 69-75.	1.9	9

#	Article	IF	Citations
181	Vascular Access for Hemodialysis and Value-Based Purchasing for ESRD. Journal of the American Society of Nephrology: JASN, 2017, 28, 395-397.	6.1	9
182	Attitudes toward Peritoneal Dialysis among Peritoneal Dialysis and Hemodialysis Medical Directors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1067-1070.	4.5	9
183	Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial. American Journal of Kidney Diseases, 2021, 77, 12-22.	1.9	9
184	Medicaid Expansion and Incidence of Kidney Failure among Nonelderly Adults. Journal of the American Society of Nephrology: JASN, 2021, 32, 1425-1435.	6.1	9
185	Patient-reported outcome measures for life participation in peritoneal dialysis: a systematic review. Nephrology Dialysis Transplantation, 2021, 36, 890-901.	0.7	9
186	Establishing a core outcome measure for life participation in patients receiving peritoneal dialysis: A Standardised Outcomes in Nephrologyâ€“Peritoneal Dialysis consensus workshop report. Peritoneal Dialysis International, 2022, 42, 562-570.	2.3	7
187	Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists. American Journal of Kidney Diseases, 2004, 44, 309-321.	1.9	6
188	Estimated GFR Reporting Influences Recommendations for Dialysis Initiation. Journal of the American Society of Nephrology: JASN, 2013, 24, 1737-1742.	6.1	6
189	Advancing American Kidney Healthâ€”New Opportunities for Collaborative Care. American Journal of Medicine, 2020, 133, e335-e337.	1.5	6
190	Despite National Declines In Kidney Failure Incidence, Disparities Widened Between Low- And High-Poverty US Counties. Health Affairs, 2021, 40, 1900-1908.	5.2	6
191	Is Female Sex Really a Risk Factor for Infectious Death in Peritoneal Dialysis?. Peritoneal Dialysis International, 2013, 33, 475-478.	2.3	5
192	Racial Differences in Survival of Incident Home Hemodialysis and Kidney Transplant Patients. Transplantation, 2016, 100, 2203-2210.	1.0	5
193	â€œCan I go to Glasgow?â€•Learnings from patient involvement at the 17th Congress of the International Society for Peritoneal Dialysis (ISPD). Peritoneal Dialysis International, 2020, 40, 12-25.	2.3	5
194	Patient Activation Measure in Dialysis Dependent Patients in the United States. Journal of the American Society of Nephrology: JASN, 2021, , ASN.2021030315.	6.1	5
195	Change in ankle-brachial index over time and mortality in diabetics with proteinuria. Clinical Nephrology, 2012, 78, 335-345.	0.7	5
196	Impact of Removing Race Variable on CKD Classification Using the Creatinine-Based 2021 CKD-EPI Equation. Kidney Medicine, 2022, 4, 100471.	2.0	5
197	Longitudinal Evaluation of a Renal Kt/VUrea of 2.0 as a Threshold for Initiation of Dialysis. ASAIO Journal, 1998, 44, M677-M681.	1.6	4
198	Searching for new care models for chronic kidney disease. Kidney International, 2012, 82, 621-623.	5.2	4

#	Article	IF	Citations
199	Expanding Access to Peritoneal Dialysis for Incident Dialysis Patients. American Journal of Kidney Diseases, 2012, 59, 330-332.	1.9	4
200	Should Glucose-Sparing Prescriptions Be Expected to Reduce the Cardiovascular Risk of Peritoneal Dialysis Patients?. Journal of the American Society of Nephrology: JASN, 2013, 24, 1713-1716.	6.1	4
201	New-Onset Diabetes in Peritoneal Dialysis Patients â€“ Which Predictors Really Matter?. Peritoneal Dialysis International, 2016, 36, 243-246.	2.3	4
202	Peritoneal Dialysis Should be the First Choice of Initial Renal Replacement Therapy for More Patients With End-Stage Renal Disease. ASAIO Journal, 2001, 47, 309-311.	1.6	4
203	Scope and heterogeneity of outcomes reported in randomized trials in patients receiving peritoneal dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1817-1825.	2.9	4
204	Reducing peritonitis rates in a peritoneal dialysis program of indigent ethnic minorities. Peritoneal Dialysis International, 2003, 23, 83-5.	2.3	4
205	Changing patterns of peritoneal dialysis utilization in the United States. Peritoneal Dialysis International, 2007, 27 Suppl 2, S51-2.	2.3	4
206	International Icodextrin Use and association with peritoneal membrane function, fluid removal, patient and technique survival. Kidney360, 0, , 10.34067/KID.0006922021.	2.1	4
207	Translating an Understanding of the Determinants of Technique Failure to Maximize Patient Time on Peritoneal Dialysis?. Peritoneal Dialysis International, 2013, 33, 112-115.	2.3	3
208	Surviving the First Year of Peritoneal Dialysis: Enduring HardÂTimes. American Journal of Kidney Diseases, 2014, 64, 673-676.	1.9	3
209	The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360, 2021, 2, 445-455.	2.1	3
210	Ambulatory and Home Blood Pressure Monitoring in Hemodialysis Patients: A Mixed-Methods Study Evaluating Comparability and Tolerability of Blood Pressure Monitoring. Kidney Medicine, 2021, 3, 457-460.	2.0	3
211	Measuring Vascular Calcification Clinical Practice. Seminars in Dialysis, 2010, 23, 263-266.	1.3	2
212	CJASN: Turning the Page. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1-2.	4.5	2
213	Numbers or symptoms: when to initiate dialysis?. Nephrology Dialysis Transplantation, 2018, 33, 904-905.	0.7	2
214	CJASN: Whatâ€™s Behind and Whatâ€™s Ahead. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 3-3.	4.5	2
215	Trends in Mortality Among Patients Initiating Maintenance Dialysis in Puerto Rico Compared to US States, 2006-2015. American Journal of Kidney Diseases, 2020, 75, 296-298.	1.9	2
216	Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360, 2020, 1, 1380-1389.	2.1	2

#	Article	IF	Citations
217	Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism. American Journal of Nephrology, 2022, 53, 157-168.	3.1	2
218	Another Call for Timely Initiation of Dialysis. Blood Purification, 2000, 18, 313-316.	1.8	1
219	Health Insurance, Access to Care, and ESRD: An Intricate Web. Journal of the American Society of Nephrology: JASN, 2014, 25, 1135-1136.	6.1	1
220	Young Kidney Professionalsâ€™ Perspectives and Attitudes about Consuming Scientific Information. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1587-1597.	4.5	1
221	CJASN and Disclosure of Conflicts of Interest. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 785-786.	4.5	1
222	Emphasizing patient choice: the modality selection project in ESRD Network 18. Nephrology News & Issues, 2003, 17, 30-6.	0.1	1
223	The John F. Maher Award Recipient Lecture 2006. The continuum of chronic kidney disease and end-stage renal disease: challenges and opportunities for chronic peritoneal dialysis in the United States. Peritoneal Dialysis International, 2007, 27, 125-30.	2.3	1
224	Comparison of mortality between Medicare Advantage and traditional Medicare beneficiaries with kidney failure. American Journal of Managed Care, 2022, 28, 180-186.	1.1	1
225	Strong association of carotid plaques with mortality and cardiovascular morbidity in hemodialysis patients. Nature Clinical Practice Nephrology, 2006, 2, 620-621.	2.0	0
226	144. American Journal of Kidney Diseases, 2007, 49, B60.	1.9	0
227	60: Mortality Trend of Hemodialysis Chains in the USA: 1996-2004. American Journal of Kidney Diseases, 2008, 51, B42.	1.9	0
228	96: Comparing Mortality of Chronic Peritoneal and Maintenance Hemodialysis Patients in the 21st Century Up to 5 Years. American Journal of Kidney Diseases, 2008, 51, B51.	1.9	0
229	84 Comparing Mortality Risk of Minerals, PTH and Alkaline Phosphatase Over 6 Years in 12,422 Chronic Peritoneal Dialysis (CPD) Patients. American Journal of Kidney Diseases, 2011, 57, B37.	1.9	0
230	American Society of Nephrology Quiz and Questionnaire 2012: Renal Replacement Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1632-1636.	4.5	0
231	Introduction to 30ÂYears: Lessons Learned in Dialysis. Seminars in Dialysis, 2017, 30, 85-85.	1.3	0
232	Perspectives on Funding Initiatives in Clinical Research in Kidney Disease in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1543-1543.	4.5	0
233	FP495PATIENT AND CAREGIVER PRIORITIES FOR OUTCOMES IN PERITONEAL DIALYSIS: AN INTERNATIONAL NOMINAL GROUP STUDY. Nephrology Dialysis Transplantation, 2018, 33, i205-i205.	0.7	0
234	MO680INTERNATIONAL COMPARISONS OF ICODEXTRIN PRESCRIPTION PRACTICE AND ITS ASSOCIATION WITH FLUID REMOVAL, BLOOD PRESSURE, PATIENT AND TECHNIQUE SURVIVAL*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0

#	Article	IF	Citations
235	Looking for adequate return on investment: timing of educating patients about dialysis modalities. Peritoneal Dialysis International, 2008, 28, 347-8.	2.3	0